Frankel Wendy L, Jin Ming
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Mod Pathol. 2015 Jan;28 Suppl 1:S95-108. doi: 10.1038/modpathol.2014.128.
Colorectal carcinoma is the third most common cancer in the United States. Proper and standardized pathologic staging is vital for prognostic assessment and impacts therapeutic decisions. The Tumor Node Metastasis (TNM) staging system was developed by the American Joint Committee on Cancer (AJCC) to be a data-driven, evidence-based staging system providing an accurate prediction of outcome. The AJCC 7th edition (2010) included several changes clarifying some issues and leading to new controversies. We aim to address selected challenging issues in tumor T staging, neoadjuvant treatment effects in rectal cancer, and definition of lymph node vs tumor deposit. Serosal involvement in colorectal cancer is staged as T4, which is associated with decreased survival and may impact additional therapy decisions. Although careful sampling and sectioning are helpful, challenges remain in interpretation of tumor within 1 mm of serosal surface with a reaction. Elastic stain as a surrogate marker for serosal invasion has been studied, but its usefulness remains unclear. Some unique issues in rectal cancer include the presence of serosa in proximal but not in distal tumors and post-neoadjuvant effects. Tumor should be staged based on tumor cells rather than acellular mucin pools. Additionally, tumor response should be graded only in primary tumor but not in lymph nodes or metastatic sites. The distinction between tumor deposits and lymph nodes has been modified in AJCC TNM from using size in the 5th edition, to the round contour in the 6th edition, to only features of residual lymph node architecture in the 7th edition. Interobserver variability remains but tumor deposits should be documented when present. The number of deposits should not be added to the total number of positive lymph nodes, and the N1c designation should only be used in cases without any positive lymph nodes. Future clarification will likely evolve as more data become available.
结直肠癌是美国第三大常见癌症。恰当且标准化的病理分期对于预后评估至关重要,并会影响治疗决策。肿瘤-淋巴结-转移(TNM)分期系统由美国癌症联合委员会(AJCC)制定,是一个基于数据、循证的分期系统,能够准确预测预后。AJCC第7版(2010年)有几处改动,澄清了一些问题,但也引发了新的争议。我们旨在解决肿瘤T分期、直肠癌新辅助治疗效果以及淋巴结与肿瘤沉积物定义等方面的一些具有挑战性的问题。结直肠癌的浆膜受累归为T4期,这与生存率降低相关,可能会影响额外的治疗决策。尽管仔细采样和切片有所帮助,但对于距浆膜表面1毫米内有反应的肿瘤的解读仍存在挑战。弹性染色作为浆膜侵犯的替代标志物已被研究,但其效用仍不明确。直肠癌的一些独特问题包括近端肿瘤有浆膜而远端肿瘤没有,以及新辅助治疗后的影响。肿瘤应根据肿瘤细胞而非无细胞粘蛋白池进行分期。此外,肿瘤反应应仅在原发肿瘤中分级,而不在淋巴结或转移部位分级。AJCC TNM中肿瘤沉积物与淋巴结的区分已从第5版使用大小,改为第6版使用圆形轮廓,再到第7版仅依据残余淋巴结结构特征。观察者间的差异仍然存在,但肿瘤沉积物存在时应记录。沉积物的数量不应加到阳性淋巴结总数中,且N1c分类仅应用于无任何阳性淋巴结的病例。随着更多数据可用,未来可能会有进一步的澄清。